22-May-2025
Experimental drug may benefit some patients with rare form of ALS
Columbia University Irving Medical CenterPeer-Reviewed Publication
Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery.
- Journal
- The Lancet
- Funder
- NIH/National Institutes of Health, ALS Association, Project ALS, Ionis Pharmaceuticals, Tow Foundation, Nancy D Perlman and Thomas D Klingenstein Innovation Fund for Neurodegenerative Disease, American Academy of Neurology, American Brain Foundation, CReATe Consortium, Angel Fund for ALS Research, Cellucci Fund for ALS Research, Max Rosenfeld ALS Fund, University of Minnesota, Muscular Dystrophy Association